M89
目录号 : GC36521
M-89 强效的、特异性的menin 的抑制剂，结合到menin 的Kd 值为1.4 nM。M-89 可抑制Menin-MLL 蛋白之间的相互作用，有治疗混合谱系白血病的潜力。
Cas No.:2363165-42-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia[1]. Kd: 1.4 nM (menin)[1].
[1]. Aguilar A, et al. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. J Med Chem. 2019 Jul 11;62(13):6015-6034.
| Cas No. | 2363165-42-6 | SDF | |
| Canonical SMILES | O=C(OC)N[C@@H]1[C@@H]([C@]2(C3CCN(CC4CN(C5=CC=C(S(=O)(C6=CC=NC=C6)=O)C=C5)C4)CC3)CN(C)CC7=C2C=CC=C7)CCC1 | ||
| 分子式 | C37H47N5O4S | 分子量 | 657.87 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5201 mL | 7.6003 mL | 15.2006 mL |
| 5 mM | 0.304 mL | 1.5201 mL | 3.0401 mL |
| 10 mM | 0.152 mL | 0.76 mL | 1.5201 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Complete Genome Sequences of Streptococcus pyogenes Serotype M3, M28, and M89 Strains Isolated from Human Patients in Japan, 1994 to 2009
Microbiol Resour Announc 2020 Oct 15;9(42):e01047-20.PMID:33060279DOI:10.1128/MRA.01047-20.
Streptococcus pyogenes (group A Streptococcus [GAS]) is a major human pathogen that occasionally causes severe and life-threatening invasive diseases. Here, we report the complete genome sequences of four GAS strains of three M types, which were isolated from patients with severe invasive disease in Japan.
Mitogenic factor (MF) is the major DNase of serotype M89 Streptococcus pyogenes
Microbiology (Reading) 2000 Nov;146 ( Pt 11):2785-2792.PMID:11065357DOI:10.1099/00221287-146-11-2785.
To investigate the role of mitogenic factor (MF) in streptococcal pathogenesis, the structural gene (mf) encoding this protein was disrupted in a clinical isolate of Streptococcus pyogenes H293, to yield the isogenic mutant H363. Growth in enriched broth and on blood agar was unaffected by disruption of mf. Cell-free broth supernatants from H293 and H363 demonstrated identical promitogenic activities when co-incubated with human peripheral blood mononuclear cells, even when diluted 100000-fold, showing that MF is not a major streptococcal mitogen compared with other secreted superantigens. Disruption of mf resulted in complete loss of DNase B production and detectable DNase activity in H363 compared with the parent strain, confirming that the single gene mf, which is present in all group A streptococcal M serotypes studied, encodes DNase B. Despite loss of DNase activity, the virulence of S. pyogenes in a mouse model of necrotizing fasciitis and myositis was unaffected.
Evaluation of the efficacy and tolerance of a cosmetic mask containing 89% of vichy volcanic mineralizing water and hyaluronic acid after facial laser procedures
J Cosmet Dermatol 2021 Sep;20(9):2860-2866.PMID:33538111DOI:10.1111/jocd.13972.
Background: M89 M (Mineral 89 mask, Laboratoires Vichy, France), containing 89% Vichy volcanic mineralizing water and hyaluronic acid, aims to strengthen and repair skin barrier. Aims: To assess the efficacy, tolerance, patient satisfaction, and quality of life (QOL) using M89 M after laser procedures (LP). Methods: M89 M was applied immediately post-LP for 10 minutes, then daily for 5 days and 2-3 times a week, up to 28 days on the faces of 51 women. Evaluations were performed immediately post-LP, immediately after M89 M application at D0, D1, D5, and D28, and included criteria such as erythema and skin dryness. Subjects scored burning and warm sensations, itching, skin tightness, and stinging. Skin hydration using a Corneometer, skin barrier integrity using a Tewameter, and erythema using a Chromameter were assessed. Local tolerance and adverse events were recorded. After 28 days, subjects answered a questionnaire regarding the M89 M subjective cosmetic properties and QOL. Results: All subjects were in their mid-forties with a phototype of II, III, or IV. M89 M significantly (P < .001) reduced the immediate cutaneous discomfort sensation and laser procedure-related symptoms (burning, warmth sensation, itching/stinging, skin tightness). Skin hydration, and erythema, assessed using instrumental measures, were also significantly improved immediately after mask application (P ≤ .01). Subjects highly appreciated M89 M and their QOL improved after 28 days of use. Local tolerance was good to excellent in both studies. Conclusion: M89 M is effective and safe immediately after esthetic procedures such as ablative and nonablative lasers and also improves the subject's QOL.
89% Vichy mineralizing water with hyaluronic acid is a well-tolerated adjunct treatment that helps restore skin barrier function in dry skin-related inflammatory dermatoses and post-procedure skin care: A Canadian study
J Cosmet Dermatol 2021 Jul;20(7):2148-2155.PMID:33786979DOI:10.1111/jocd.14116.
Introduction: Minéral 89 (M89), comprised of 89% Vichy mineralizing water and hyaluronic acid, has been formulated to help strengthen and restore skin barrier. Aim: Assess tolerance and efficacy of M89 in post-esthetic procedures and dry skin-related facial dermatoses. Method: Adults post-esthetic procedure or presenting with inflammatory dermatoses (47 subjects; mean age 40.9 ± 13.2 years; any Fitzpatrick or skin phototype), applied M89 for 4 weeks, once or twice daily, as an adjuvant treatment. Information on clinical signs and subject-reported symptoms, skin characteristics, tolerance, and subject and investigator satisfaction were collected. Results: Following 4 weeks of M89 use, significant decreases with complete resolution of erythema (27.6%), desquamation (29.8%), irritation (32%), and skin dehydration (35.8%), as compared to baseline signs and symptoms, were observed. Overall grading improvements for erythema (84.8%; p < 0.001), desquamation (91.7%; %; p < 0.003), irritation (91.7%; %; p < 0.015), and skin hydration (46.2%; p < 0.015) were noted. There was no significant improvement in papules and pustules. Evaluation of subjective signs demonstrated significant decreases in skin sensations such as burning (-73%; p < 0.0001), itching (-71%; p < 0.0001), stinging-tingling (-66.7%; p < 0.0001), as well as in skin dryness (-60%; p < 0.0001). M89 texture was rated very pleasant by 90% of patients. Investigators assessed M89 tolerance to be either good or very good (93%), and satisfactory or highly satisfactory impact on patient's skin (91.5%). Conclusion: M89 is a highly tolerable adjuvant treatment that significantly improved clinical signs and symptoms related to a compromised skin barrier in various facial dermatoses and post-aesthetic procedures.
A Split-Face Study Assessing the Clinical Benefit, Tolerability and Subject Satisfaction of a Dermocosmetic in Subjects with Rosacea Associated with Erythema and Sensitive Skin
Clin Cosmet Investig Dermatol 2020 Oct 5;13:751-758.PMID:33116738DOI:10.2147/CCID.S266879.
Objective: This study assessed the efficacy and tolerability of M89 in patients with rosacea associated with erythema and sensitive skin. Methods: Intra-individual study in a split-face design comparing after 30 days M89 twice daily and usual skin care in 20 adult subjects with rosacea and sensitive skin. M89 contains 89% Vichy volcanic mineralizing water (VVMW) and 0.4% hyaluronic acid. It is hypoallergenic and contains no perfume and this convenes in rosacea. Contained minerals reinforce the natural defences of the skin in restoring the natural skin barrier, stimulating antioxidant activity and reducing inflammation, commonly observed in subjects with rosacea. Clinical evaluations included assessment of erythema, desquamation, papules and pustules, skin tightness, dryness, burning sensation, itching, stinging and stinging test as well as local tolerability. Instrumental evaluations included skin hydration and TEWL. Subject satisfaction was assessed at Days 15 and 30. Demodex density was assessed at Day 30. Results: A significant superiority of M89 over the standard skin care was observed for erythema, skin tightness and dryness (all P≤0.05) as early as Day 15, the skin stinging test was significantly in favour of M89 (P<0.05 at Day 15 and P<0.01 at Day 30) and for skin hydration (P<0.0001) at Day 15 and 30 with no difference in mean Demodex density between M89 and usual skin care after 30 days. Tolerance was excellent and subject satisfaction very high. Conclusion: Study results concerning M89 are encouraging for its use either alone or as an adjuvant daily skin care to topical medication in patients with persistent centrofacial erythema of rosacea with no more than 3 papules and pustules.